"A549[A-549]人非小細(xì)胞肺癌復(fù)蘇細(xì)胞保種中心|帶STR證書(shū)

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

貼壁細(xì)胞消化傳代時(shí)通常采用兩種方法：一、加入胰酶等細(xì)胞脫落后，再加培養(yǎng)基中止胰酶作用，離心傳代；二、加入胰酶后，鏡下觀察待細(xì)胞始脫落時(shí)，棄胰酶，加培養(yǎng)分瓶。但前者太麻煩，而后者有可能對(duì)細(xì)胞施加胰酶選擇，因?yàn)榭偸琴N壁不牢的細(xì)胞先脫落，對(duì)腫瘤細(xì)胞來(lái)說(shuō)，這部分細(xì)胞有可能是惡性程度較GAO的細(xì)胞亞群。一種簡(jiǎn)單的消化傳代方法。加入PBS洗去血清或加入胰酶先中和血清的作用(３０s)，棄之，再加入適量胰酶作用１０s-４０s(根據(jù)細(xì)胞消化的難易程度)，棄之，這樣依賴殘余的胰酶就可將細(xì)胞消化單細(xì)胞。對(duì)于較難消化的細(xì)胞，可以用２%利多卡因消化５-８分鐘，然后再棄去，加培養(yǎng)基吹打也可以，對(duì)細(xì)胞的影響不大。不用PBS也不用Hanks洗，只要把舊培養(yǎng)吸的干凈一點(diǎn)，直接加酶消化應(yīng)該不會(huì)有什么問(wèn)題。棄培養(yǎng)后，用０.０４%的EDA沖洗一次，再用１/４v的０.０４%的EDA室溫孵育５min，棄取大部分EDA，加入與剩余EDA等量的胰酶(預(yù)熱)總體積１/１０v。消化到有細(xì)胞脫落。不過(guò)有人說(shuō)EDA對(duì)細(xì)胞不HAO，有證據(jù)嗎？培養(yǎng)的BASMC：倒掉舊培養(yǎng)加入少量胰酶沖一下，倒掉再加入０.１２５-０.２５%胰酶約６-１０滴或１ml(２５ml bole)消化再加入適量新培養(yǎng)基中和，并分瓶這種方法簡(jiǎn)單、省事；效果很HAO并且不損失細(xì)胞！

換液周期：每周2-3次

CHP-126 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：OKT 3細(xì)胞、CCC-HIE-2細(xì)胞、HOC1細(xì)胞

H-1238 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：ARH77細(xì)胞、Anip[973]細(xì)胞、THLE-3細(xì)胞

SKMES1 Cells;背景說(shuō)明：源于一位６５歲患有肺鱗狀細(xì)胞癌的白人男性，自轉(zhuǎn)移性胸腔積液分離而來(lái)。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MG63細(xì)胞、NU-GC-4細(xì)胞、SW-982細(xì)胞

A549[A-549]人非小細(xì)胞肺癌復(fù)蘇細(xì)胞保種中心|帶STR證書(shū)

背景信息：最初分離自一名58歲白人男性的非小細(xì)胞肺癌組織，于1972年由科學(xué)家D. J. Giard等人培養(yǎng)成功。能通過(guò)胞苷二磷酸膽堿途徑合成含有高含量不飽和脂肪酸的卵磷脂。

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長(zhǎng)速率、鋪板效率、生長(zhǎng)條件和生長(zhǎng)特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長(zhǎng)的快速生長(zhǎng)細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長(zhǎng)期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個(gè)容器轉(zhuǎn)移到另一個(gè)容器的過(guò)程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長(zhǎng)期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長(zhǎng)。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

AN3CA Cells;背景說(shuō)明：AN３CA細(xì)胞建系于１９６４年。它衍生于子宮內(nèi)膜癌患者淋巴結(jié)轉(zhuǎn)移組織，具有癌細(xì)胞的基本特性，能在體外長(zhǎng)期傳代培養(yǎng)，接種實(shí)驗(yàn)動(dòng)物產(chǎn)生明顯腫瘤。但細(xì)胞的生物學(xué)特性及超微結(jié)構(gòu)尚未深入研究，僅發(fā)現(xiàn)該細(xì)胞系促黑激素合成為陰性。細(xì)胞常用于人子宮內(nèi)膜癌細(xì)胞生物學(xué)及其相關(guān)特性研究。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MB 157細(xì)胞、C6661細(xì)胞、Rat podocyte細(xì)胞

GM00346B Cells;背景說(shuō)明：皮下結(jié)締組織；自發(fā)永生；雄性；C３H/An;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：ReNcell CX細(xì)胞、RCC10 RGB細(xì)胞、TR-146細(xì)胞

Hs 611.T Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；每周換液２-３次。;生長(zhǎng)特性：混合型;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：PE/CA-PJ34 (clone C12)細(xì)胞、P3/X63-Ag8細(xì)胞、HPAF/CD18細(xì)胞

WC00044 Cells;背景說(shuō)明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HEK 293 EBNA細(xì)胞、Stanford University-Diffuse Histiocytic Lymphoma-16細(xì)胞、MDA-175細(xì)胞

A549[A-549]人非小細(xì)胞肺癌復(fù)蘇細(xì)胞保種中心|帶STR證書(shū)

物種來(lái)源：人源、鼠源等其它物種來(lái)源

形態(tài)特性：上皮細(xì)胞樣

其實(shí)絕大部分細(xì)胞消化的時(shí)候是只要用胰酶潤(rùn)洗一遍即可，吸去胰酶后，殘留的那些無(wú)法計(jì)算體積的附著在細(xì)胞表面的微量胰酶在３７度一般不到２min足夠消化細(xì)胞(絕大部分１min不到)。對(duì)于這些細(xì)胞原則上不要用胰酶孵育細(xì)胞，連續(xù)這樣傳代，對(duì)細(xì)胞傷害很大。簡(jiǎn)單的程序是PBS潤(rùn)洗吸去，胰酶潤(rùn)洗吸去，然后３７度消化；什么算是消化HAO了呢？不是細(xì)胞全部成間隔分布很離散的單個(gè)圓形才算消化HAO了，一般你肉眼觀察貼壁細(xì)胞層，只要能移動(dòng)了，多半呈沙壯移動(dòng)，其實(shí)已經(jīng)可以了，很多人喜歡把細(xì)胞消化或者吹打成完全分離細(xì)胞，這是沒(méi)有必要的。一般能移動(dòng)了，說(shuō)明細(xì)胞與培養(yǎng)基質(zhì)材料的附著已經(jīng)消失了，細(xì)胞之間的附著也已經(jīng)消失了，細(xì)胞已經(jīng)獨(dú)立分布了(雖然沒(méi)有呈現(xiàn)很廣的離散分布)。這個(gè)時(shí)候應(yīng)該停止消化，不要等到看到鏡下所有細(xì)胞都分離得非常HAO，間隙很大，才停止。細(xì)胞就是完全成單個(gè)細(xì)胞懸，之后在貼壁的過(guò)程中仍然會(huì)聚集，這個(gè)是貼壁培養(yǎng)的細(xì)胞，尤其是腫瘤細(xì)胞的一個(gè)性，無(wú)論死活的細(xì)胞都是如此，你可以嘗試，準(zhǔn)備１００%的單個(gè)細(xì)胞懸，貼壁后觀察細(xì)胞，仍然是幾個(gè)幾個(gè)細(xì)胞聚集在一起。一些懸浮培養(yǎng)細(xì)胞也是如此，容易聚集，不要去嘗試過(guò)幾個(gè)小時(shí)就拿出來(lái)吹打成單細(xì)胞懸(不要笑，這個(gè)是初養(yǎng)懸浮細(xì)胞的人常犯的錯(cuò)誤，以為懸浮培養(yǎng)就是一個(gè)一個(gè)分開(kāi))。細(xì)胞只要能從基質(zhì)上脫離下來(lái)，這個(gè)時(shí)候即使是成片的(比如Calu-３細(xì)胞)，吹打不超過(guò)２０次后(一般１０次即可)，成小規(guī)模聚集(１０個(gè)細(xì)胞左右)，是正常的，不要試圖再去延長(zhǎng)消化時(shí)間，或者像有的同學(xué)那樣吹打１h，等待單細(xì)胞懸出現(xiàn)。

KTCTL140 Cells;背景說(shuō)明：腎透明細(xì)胞癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H-2009細(xì)胞、Evsa-T細(xì)胞、COLO 678細(xì)胞

RASMC Cells;背景說(shuō)明：主動(dòng)脈；平滑肌 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：OCI-Ly8細(xì)胞、TPC-1細(xì)胞、WSU-DLCL-2細(xì)胞

BHK Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代，每周換液１-２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：TEC細(xì)胞、I90細(xì)胞、H2085細(xì)胞

alpha TC1 clone 6 Cells;背景說(shuō)明：胰島素瘤；a細(xì)胞；C５７BL/６xDBA/２;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Leukemic 1210細(xì)胞、COLO-320-HSR細(xì)胞、H19-7細(xì)胞

COLO 357 Cells;背景說(shuō)明：胰腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MB-49細(xì)胞、PC 61-5-3細(xì)胞、AR42J細(xì)胞

D283 Med Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮細(xì)胞的多細(xì)胞聚集體，和一些貼壁 Cells;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：253JB-V細(xì)胞、L 428細(xì)胞、BC3H1細(xì)胞

GM02132C Cells;背景說(shuō)明：來(lái)源于一位６１歲的男性漿細(xì)胞瘤患者；可產(chǎn)生免疫球蛋白輕鏈，未檢測(cè)到重鏈。;傳代方法：按１：２傳代，５-６小時(shí)可以看到細(xì)胞分裂;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HR-8348細(xì)胞、GLC82細(xì)胞、MC57G細(xì)胞

HCC-38 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KLM1細(xì)胞、KE39細(xì)胞、SW-756細(xì)胞

SK.MEL.5 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：星形的;相關(guān)產(chǎn)品有：Co 115細(xì)胞、HCT.116細(xì)胞、PLA801C細(xì)胞

MB-49 Cells;背景說(shuō)明：膀胱癌；雄性；C５７BL/Icrfa(t);傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HT29細(xì)胞、KOPN-8細(xì)胞、UC-3細(xì)胞

HcaF Cells;背景說(shuō)明：肝癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H8細(xì)胞、YD-15細(xì)胞、RT-112細(xì)胞

MILE SVEN1 Cells;背景說(shuō)明：MS１是１９９４年建株的胰島內(nèi)皮細(xì)胞株。原代培養(yǎng)的胰島內(nèi)皮細(xì)胞用抗G４１８的溫度敏感型SV４０大T抗原(tsA-５８-３)轉(zhuǎn)染?？剐钥寺∮每寺…h(huán)分離，并篩選吸收dil-Ac-LDL的。這株細(xì)胞保留了內(nèi)皮細(xì)胞的許多特性，如吸收乙酰化LDL和表達(dá)八因子相關(guān)抗原及BEGF受體。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：3T3-A31細(xì)胞、HuH7細(xì)胞、IFRS1細(xì)胞

NIH3T3 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MGH-U1細(xì)胞、266 Bl細(xì)胞、TE-4細(xì)胞

293S Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CL-34細(xì)胞、LC1sq細(xì)胞、RBL-2H3細(xì)胞

HCO Cells;背景說(shuō)明：顱骨；成骨 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SNU368細(xì)胞、Wien 133細(xì)胞、SJSA-1細(xì)胞

SKN-AS Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：５-１：１０傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H1238細(xì)胞、Glioma-261細(xì)胞、Earle's L cells細(xì)胞

IOSE 80 Cells;背景說(shuō)明：卵巢；上皮細(xì)胞；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H2330細(xì)胞、NALM-6細(xì)胞、FHC細(xì)胞

A549[A-549]人非小細(xì)胞肺癌復(fù)蘇細(xì)胞保種中心|帶STR證書(shū)

Abcam HEK293 DIAPH1 KO Cells(提供STR鑒定圖譜)

AG08615 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line KST109 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XB748 Cells(提供STR鑒定圖譜)

BP8 Cells(提供STR鑒定圖譜)

CoE 45 Cells(提供STR鑒定圖譜)

DA03814 Cells(提供STR鑒定圖譜)

DA05324 Cells(提供STR鑒定圖譜)

GENEA057 Cells(提供STR鑒定圖譜)

OCI-Ly 8 Cells;背景說(shuō)明：彌漫大B淋巴瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：K562/ADP細(xì)胞、MOLT3細(xì)胞、MDA-MB-436細(xì)胞

Hs-27 Cells;背景說(shuō)明：包皮；成纖維細(xì)胞；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SKNBE2細(xì)胞、NTERA2-D1細(xì)胞、SNU5細(xì)胞

NCI-H64 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HepaRG細(xì)胞、D-324 Med細(xì)胞、McA-RH7777細(xì)胞

SJSA-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：５-１：１０傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：PECAPJ34細(xì)胞、HAC-84細(xì)胞、MDA.MB.435細(xì)胞

CHP 126 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H-23細(xì)胞、OVCAR.3細(xì)胞、Cates-1B細(xì)胞

KM12 SM Cells;背景說(shuō)明：結(jié)腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Madin Darby Bovine Kidney細(xì)胞、SCH細(xì)胞、GAK細(xì)胞

1B3-18 Cells(提供STR鑒定圖譜)

RIN Cl-5F Cells;背景說(shuō)明：胰島β細(xì)胞瘤；雄性；NEDH;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SNB19細(xì)胞、HCC9204細(xì)胞、GM15452細(xì)胞

GDM1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：２-３天換液１次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：Jurkat-FHCRC細(xì)胞、WPMY-1細(xì)胞、MKN-1細(xì)胞

HCe-8693 Cells;背景說(shuō)明：盲腸腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MOLM-16細(xì)胞、UACC893細(xì)胞、OCIAML5細(xì)胞

OCI-AML-5 Cells;背景說(shuō)明：急性髓系白血病細(xì)胞；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SNU398細(xì)胞、16HBE細(xì)胞、SK-N-BE(2C)細(xì)胞

HFT 8810 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CAL-85-1細(xì)胞、MPC 11細(xì)胞、HEC-151細(xì)胞

RKOAS451 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：T2(174 x CEM.T2)細(xì)胞、H-2141細(xì)胞、H-820細(xì)胞

HMO6 Cells;背景說(shuō)明：小膠質(zhì) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NG 108-15細(xì)胞、CNE2Z細(xì)胞、H-378細(xì)胞

HEK293 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：U-343-MG細(xì)胞、HIMEC細(xì)胞、Murine Carcinoma-38細(xì)胞

GM10018 Cells(提供STR鑒定圖譜)

HAP1 BTBD9 (-) Cells(提供STR鑒定圖譜)

Acanthosis Nigricans 3rd attempt-CArcinoma Cells;背景說(shuō)明：AN３CA細(xì)胞建系于１９６４年。它衍生于子宮內(nèi)膜癌患者淋巴結(jié)轉(zhuǎn)移組織，具有癌細(xì)胞的基本特性，能在體外長(zhǎng)期傳代培養(yǎng)，接種實(shí)驗(yàn)動(dòng)物產(chǎn)生明顯腫瘤。但細(xì)胞的生物學(xué)特性及超微結(jié)構(gòu)尚未深入研究，僅發(fā)現(xiàn)該細(xì)胞系促黑激素合成為陰性。細(xì)胞常用于人子宮內(nèi)膜癌細(xì)胞生物學(xué)及其相關(guān)特性研究。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：U251細(xì)胞、SNU1040細(xì)胞、MLFC細(xì)胞

PL 45 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：RK 13細(xì)胞、HC-11細(xì)胞、Human Embryo Lung-1細(xì)胞

OVCA-433 Cells;背景說(shuō)明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HOS細(xì)胞、NCC-IT細(xì)胞、Bowes melanoma cells細(xì)胞

MDA-MB435 Cells;背景說(shuō)明：乳腺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BHK-21細(xì)胞、Me-Wo細(xì)胞、NCI-H1238細(xì)胞

NSI/1-Ag4-1 Cells;背景說(shuō)明：這是P３X６３Ag８(ATCCTIB-９)的一個(gè)不分泌克隆。Kappa鏈合成了但不分泌。能抗０.１mM８-氮雜鳥(niǎo)嘌呤但不能在HAT培養(yǎng)基中生長(zhǎng)。據(jù)報(bào)道它是由于缺失了３-酮類固醇還原酶活性的膽固醇營(yíng)養(yǎng)缺陷型。檢測(cè)表明肢骨發(fā)育畸形病毒(鼠痘)陰性。;傳代方法：１：２傳代，３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：NCI-H2066細(xì)胞、Nthy-ori 3.1細(xì)胞、alpha TC1 clone 6細(xì)胞

ChaGo-K1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：８?jìng)鞔?；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：U-118 MG細(xì)胞、MDA-330細(xì)胞、alpha TC1.6細(xì)胞

YES-2 Cells;背景說(shuō)明：食管鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H889細(xì)胞、OCI-LY-18細(xì)胞、BNL 1MEA.7R.1細(xì)胞

MC-26 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HCC-1428細(xì)胞、C3A細(xì)胞、Hs 683細(xì)胞

HG03466 Cells(提供STR鑒定圖譜)

ID00085 Cells(提供STR鑒定圖譜)

LOPRA-1/4 Cells(提供STR鑒定圖譜)

NCI-H69/IFN-gamma Cells(提供STR鑒定圖譜)

PathHunter U2OS HTR1F beta-arrestin Cells(提供STR鑒定圖譜)

Ubigene HeLa VIPR2 KO Cells(提供STR鑒定圖譜)

XPHM12BE Cells(提供STR鑒定圖譜)

hFIB2-iPS5 Cells(提供STR鑒定圖譜)

E304 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SR-786細(xì)胞、3LL細(xì)胞、U138細(xì)胞

WM 266-4 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CMT 167細(xì)胞、SNU484細(xì)胞、CTLL-2細(xì)胞

NuTu-19 Cells;背景說(shuō)明：卵巢癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SUP-B15細(xì)胞、WI 38細(xì)胞、Tb 1-Lu細(xì)胞

LN 229 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代；每周換液２-３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：RBMVEC細(xì)胞、SUM 52PE細(xì)胞、COLO-679細(xì)胞

AML 12 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Kit225 K6細(xì)胞、NCI-H1882細(xì)胞、NCIN87細(xì)胞

AML 12 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Kit225 K6細(xì)胞、NCI-H1882細(xì)胞、NCIN87細(xì)胞

Lilly Laboratories Cell-Porcine Kidney 1 Cells;背景說(shuō)明：腎；自發(fā)永生；Hampshire;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LIM 1215細(xì)胞、HMC-1細(xì)胞、HuH28細(xì)胞

Mv1.Lu Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA-MB-361細(xì)胞、H1975細(xì)胞、P3X63細(xì)胞

KALS-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多邊形;相關(guān)產(chǎn)品有：RA 1細(xì)胞、SUDHL1細(xì)胞、OVCA433細(xì)胞

MC57 Cells;背景說(shuō)明：纖維肉瘤；C５７BL/６J;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NB19-RIKEN細(xì)胞、Moorfields/Institute of Ophthalmology-Muller 1細(xì)胞、NPA細(xì)胞

AG 9 Cells;背景說(shuō)明：皮下結(jié)締組織；自發(fā)永生；雄性；C３H/An;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Ramos-RA1細(xì)胞、IAR20細(xì)胞、NCIH345細(xì)胞

Alexander Cells;背景說(shuō)明：該細(xì)胞系分泌乙肝病毒表面抗原（HBsAg）。 此細(xì)胞系原先被支原體污染，后用BM-cycline去除支原體;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：IPLB-SF-21-AE細(xì)胞、95D細(xì)胞、Sp2/0-Ag-14細(xì)胞

THC-8307 Cells;背景說(shuō)明：高分化結(jié)腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LS 123細(xì)胞、SW-403細(xì)胞、Medical Research Council cell strain-9細(xì)胞

Kit225/K6 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：J111細(xì)胞、GM00215細(xì)胞、OCI-AML4細(xì)胞

PANC-1 Cells;背景說(shuō)明：這株人胰腺癌細(xì)胞株源自于胰腺癌導(dǎo)管細(xì)胞，其倍增時(shí)間為５２小時(shí)。染色體研究表明，該細(xì)胞染色體眾數(shù)為６３，包括３個(gè)獨(dú)特標(biāo)記的染色體和１個(gè)小環(huán)狀染色體。該細(xì)胞的生長(zhǎng)可被１unit/ml的左旋天冬酰胺酶抑制；能在軟瓊脂上生長(zhǎng)；能在裸鼠上成瘤。;傳代方法：１：２-１：４傳代；每周２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：HIEC-6細(xì)胞、HIT T15細(xì)胞、Leghorn Male Hepatoma cell line細(xì)胞

SBB-W1 Cells(提供STR鑒定圖譜)

Hs-578Bst Cells;背景說(shuō)明：乳腺 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MN 60細(xì)胞、P3-Jiyoye細(xì)胞、UMR-106細(xì)胞

Japanese Tissue Culture-39 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCT-8細(xì)胞、Human Embryo Lung-1細(xì)胞、LLC-PK(1)細(xì)胞

Homo sapiens No. 578, tumor cells Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HS852.T細(xì)胞、NCI-H146細(xì)胞、Giant Cell Tumor細(xì)胞

WM-451Lu Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MD Anderson-Metastatic Breast-453細(xì)胞、H-1666細(xì)胞、LN-18細(xì)胞

TFK-1 Cells;背景說(shuō)明：膽管癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：PNT1A細(xì)胞、MES-SA-Dx5細(xì)胞、MDA PCa 2b細(xì)胞

Moorfields/Institute of Ophthalmology-Muller 1 Cells;背景說(shuō)明：視網(wǎng)膜Muller細(xì)胞；自發(fā)永生；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：PC 12細(xì)胞、NCI-H810細(xì)胞、Hs 578.T細(xì)胞

CHO cell clone K1 Cells;背景說(shuō)明：１９５７年，PuckTT從成年中國(guó)倉(cāng)鼠卵巢的活檢組織建立了CHO細(xì)胞，CHO-K１是CHO的一個(gè)亞克隆。CHO-K１的生長(zhǎng)需要脯酸。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCC-95細(xì)胞、SKNSH細(xì)胞、HCC9724細(xì)胞

TE-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：OC316細(xì)胞、Sf-21細(xì)胞、HCC-1395細(xì)胞

SW 579 Cells;背景說(shuō)明：在裸鼠中成瘤(產(chǎn)生三級(jí)惡性紡錘狀巨細(xì)胞瘤)。 ;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：ATN-1細(xì)胞、WM 115細(xì)胞、EPC細(xì)胞

786-0 Cells;背景說(shuō)明：該細(xì)胞源自一位原發(fā)性腎透明細(xì)胞癌患者。該細(xì)胞有微絨毛和橋粒，能在軟瓊脂上生長(zhǎng)。此細(xì)胞生成一種PTH（甲狀旁腺素）樣的多肽，與乳癌和肺癌中生成的肽相似，其N端序列與PTH相似，具有PTH樣活性，分子量為６０００D。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCIH716細(xì)胞、SNB.19細(xì)胞、H810細(xì)胞

Caco2BBe Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：６—１：１０傳代，每周換液２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Tn-5B1-4細(xì)胞、SK-MEL-31細(xì)胞、H841細(xì)胞

H-1395 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；５-６天傳代一次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：A549-Taxol細(xì)胞、PC-3M-IE8細(xì)胞、NCI-522細(xì)胞

CHP-212 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：１０ １：５０每２ - ３周；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成神經(jīng)細(xì)胞;相關(guān)產(chǎn)品有：HOS細(xì)胞、Colon-38細(xì)胞、RBE4細(xì)胞

RTE Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代，３-４天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多角;相關(guān)產(chǎn)品有：Vero細(xì)胞、NCIH2023細(xì)胞、GM06141細(xì)胞

A549[A-549]人非小細(xì)胞肺癌復(fù)蘇細(xì)胞保種中心|帶STR證書(shū)

BayGenomics ES cell line RRR235 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHD208 Cells(提供STR鑒定圖譜)

HT22 TR/TO-rKlf9 clone 2.1 Cells(提供STR鑒定圖譜)

PCRP-HEY2-1H7 Cells(提供STR鑒定圖譜)

ERC-13 Cells(提供STR鑒定圖譜)

HPS2724 Cells(提供STR鑒定圖譜)

" "PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=842942; DOI=10.1164/arrd.1977.115.2.285

Smith B.T.

Cell line A549: a model system for the study of alveolar type II cell function.

Am. Rev. Respir. Dis. 115:285-293(1977)

PubMed=924690; DOI=10.1002/ijc.2910200505

Kerbel R.S., Pross H.F., Leibovitz A.

Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.

Int. J. Cancer 20:673-679(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Tissue Antigens 11:279-286(1978)

PubMed=375235; DOI=10.1073/pnas.76.3.1288; PMCID=PMC383236

Sherwin S.A., Sliski A.H., Todaro G.J.

Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.

Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979)

PubMed=6256643; DOI=10.1038/288724a0

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Nature 288:724-727(1980)

PubMed=22282976; DOI=10.1093/carcin/1.1.21

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.

Human tumor cell strains defective in the repair of alkylation damage.

Carcinogenesis 1:21-32(1980)

PubMed=6272398; DOI=10.1126/science.6272398

Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.

High levels of intracellular bombesin characterize human small-cell lung carcinoma.

Science 214:1246-1248(1981)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157

Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.

Differential expression of the amv gene in human hematopoietic cells.

Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=7065527; DOI=10.1164/arrd.1982.125.2.222

Hay R.J., Williams C.D., Macy M.L., Lavappa K.S.

Cultured cell lines for research on pulmonary physiology available through the American Type Culture Collection.

Am. Rev. Respir. Dis. 125:222-232(1982)

PubMed=6825208; DOI=10.1093/carcin/4.2.199

Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd

Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.

Carcinogenesis 4:199-205(1983)

PubMed=6148444; DOI=10.1093/jnci/73.4.801

Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H. Jr., Mitchell J.B.

Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.

J. Natl. Cancer Inst. 73:801-807(1984)

PubMed=6500159; DOI=10.1159/000163283

Gershwin M.E., Lentz D., Owens R.B.

Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.

Exp. Cell Biol. 52:361-370(1984)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3940644

Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

Cancer Res. 46:798-806(1986)

PubMed=3945555; DOI=10.1093/nar/14.2.843; PMCID=PMC339468

Valenzuela D.M., Groffen J.

Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene.

Nucleic Acids Res. 14:843-852(1986)

PubMed=3129183

Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R.

Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas.

Cancer Res. 48:2674-2677(1988)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=3413074; DOI=10.1073/pnas.85.16.6042; PMCID=PMC281901

Pereira-Smith O.M., Smith J.R.

Genetic analysis of indefinite division in human cells: identification of four complementation groups.

Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988)

PubMed=2388294; DOI=10.1093/jnci/82.17.1420

McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

J. Natl. Cancer Inst. 82:1420-1426(1990)

PubMed=1855224

Lehman T.A., Bennett W.P., Metcalf R.A., Welsh J.A., Ecker J., Modali R.V., Ullrich S., Romano J.W., Appella E., Testa J.R., Gerwin B.I., Harris C.C.

p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.

Cancer Res. 51:4090-4096(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=8286010

Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.

Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.

Anticancer Drug Des. 8:417-428(1993)

PubMed=8132585; DOI=10.1016/S0021-9258(17)37236-8

Siegfried J.M., Han Y.-H., DeMichele M.A.A., Hunt J.D., Gaither Davis A.L., Cuttitta F.

Production of gastrin-releasing peptide by a non-small cell lung carcinoma cell line adapted to serum-free and growth factor-free conditions.

J. Biol. Chem. 269:8596-8603(1994)

PubMed=8263009; DOI=10.1007/BF01202192

Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.

Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

J. Cancer Res. Clin. Oncol. 120:143-148(1994)

PubMed=7736387; DOI=10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q

Campling B.G., Sarda I.R., Baer K.A., Pang S.C., Baker H.M., Lofters W.S., Flynn T.G.

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.

Cancer 75:2442-2451(1995)

PubMed=8626706; DOI=10.1074/jbc.271.19.11477

Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.

Insulin-like growth factor expression in human cancer cell lines.

J. Biol. Chem. 271:11477-11483(1996)

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108

Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

Cell. Immunol. 177:176-181(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=9538136; DOI=10.3892/ijo.12.5.1103

Takaki T., Hiraki A., Uenaka A., Gomi S., Itoh K., Udono H., Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.

Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.

Int. J. Oncol. 12:1103-1109(1998)

PubMed=9636188; DOI=10.1073/pnas.95.13.7556; PMCID=PMC22681

Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D.

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Proc. Natl. Acad. Sci. U.S.A. 95:7556-7561(1998)

PubMed=9649128; DOI=10.1038/bjc.1998.361; PMCID=PMC2150402

Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.

Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

Br. J. Cancer 77:2162-2170(1998)

PubMed=9673367

Fujishita T., Mizushima Y., Kashii T., Kobayashi M.

Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.

Anticancer Res. 18:1537-1542(1998)

PubMed=10358721; DOI=10.18926/AMO/31626

Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M.

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Acta Med. Okayama 53:67-75(1999)

PubMed=10536175; DOI=10.3892/ijo.15.5.927

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Int. J. Oncol. 15:927-934(1999)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293

Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.

Mutation and expression of the DCC gene in human lung cancer.

Neoplasia 2:300-305(2000)

PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0

Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.

Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

Cancer Genet. Cytogenet. 125:87-99(2001)

PubMed=11958134

Zhan X.-Q., Guan Y.-J., Li C., Chen Z.-C., Xie J.-Y., Chen P., Liang S.-P.

Differential proteomic analysis of human lung adenocarcinoma cell line A-549 and of normal cell line HBE.

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 34:50-56(2002)

PubMed=12661003; DOI=10.1002/gcc.10196

Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12794755; DOI=10.1002/ijc.11184

Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T.

RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.

Int. J. Cancer 106:45-51(2003)

PubMed=14581340

Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.

TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

Clin. Cancer Res. 9:4705-4713(2003)

PubMed=15746151; DOI=10.1093/hmg/ddi092

Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I.

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Hum. Mol. Genet. 14:997-1007(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=15999539

Matsumura T., Takigawa N., Kiura K., Shibayama T., Chikamori M., Tabata M., Ueoka H., Tanimoto M.

Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.

In Vivo 19:717-721(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17331233; DOI=10.1186/1471-2164-8-62; PMCID=PMC1821332

Nymark P., Lindholm P.M., Korpela M.V., Lahti L., Ruosaari S., Kaski S., Hollmen J., Anttila S., Kinnula V.L., Knuutila S.

Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines.

BMC Genomics 8:62.1-62.14(2007)

PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339

Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Cancer Res. 67:2046-2053(2007)

PubMed=17511773; DOI=10.1111/j.1349-7006.2007.00507.x; PMCID=PMC11159702

Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y., Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K., Yasumoto K.

Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro.

Cancer Sci. 98:1048-1054(2007)

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Cell 131:1190-1203(2007)

PubMed=19153074; DOI=10.1093/hmg/ddp034

Medina P.P., Castillo S.D., Blanco S., Sanz-Garcia M., Largo C., Alvarez S., Yokota J., Gonzalez-Neira A., Benitez J., Clevers H.C., Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.

The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.

Hum. Mol. Genet. 18:1343-1352(2009)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846

Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

A gene-alteration profile of human lung cancer cell lines.

Hum. Mutat. 30:1199-1206(2009)

PubMed=19608861; DOI=10.1126/science.1175371

Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M.

Lysine acetylation targets protein complexes and co-regulates major cellular functions.

Science 325:834-840(2009)

PubMed=19657000

Rubporn A., Srisomsap C., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Svasti J., Sangvanich P.

Comparative proteomic analysis of lung cancer cell line and lung fibroblast cell line.

Cancer Genomics Proteomics 6:229-237(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20545000; DOI=10.3724/SP.J.1141.2010.02113

Peng K.-J., Wang J.-H., Su W.-T., Wang X.-C., Yang F.-T., Nie W.-H.

Characterization of two human lung adenocarcinoma cell lines by reciprocal chromosome painting.

Dong Wu Xue Yan Jiu 31:113-121(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Cancer Sci. 101:1891-1896(2010)

PubMed=21060948; DOI=10.1039/c0mb00055h

Yu G.-C., Xiao C.-L., Lu C.-H., Jia H.-T., Ge F., Wang W., Yin X.-F., Jia H.-L., He J.-X., He Q.-Y.

Phosphoproteome profile of human lung cancer cell line A549.

Mol. Biosyst. 7:472-479(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22278370; DOI=10.1074/mcp.M111.014050; PMCID=PMC3316730

Geiger T., Wehner A., Schaab C., Cox J., Mann M.

Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.

Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22313637; DOI=10.4161/cbt.19238

Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Cancer Biol. Ther. 13:369-378(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22481983; DOI=10.2174/1874091X01206010016; PMCID=PMC3314867

Chauhan V., Howland M., Wilkins R.C.

Effects of alpha-particle radiation on microRNA responses in human cell-lines.

Open Biochem. J. 6:16-22(2012)

PubMed=22576795; DOI=10.3892/or.2012.1763

Ashinuma H., Takiguchi Y., Kitazono S., Kitazono-Saitoh M., Kitamura A., Chiba T., Tada Y., Kurosu K., Sakaida E., Sekine I., Tanabe N., Iwama A., Yokosuka O., Tatsumi K.

Antiproliferative action of metformin in human lung cancer cell lines.

Oncol. Rep. 28:8-14(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922

Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J.S., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Cancer Discov. 2:798-811(2012)

DOI=10.5897/IJBMBR2013.0154

Iloki Assanga S.B., Gil-Salido A.A., Lewis Lujan L.M., de Jesus Rosas-Durazo A., Acosta-Silva A.L., Rivera-Castaneda E.G., Rubio-Pino J.L.

Cell growth curves for different cell lines and their relationship with biological activities.

Int. J. Biotechnol. Mol. Biol. Res. 4:60-70(2013)

PubMed=23325432; DOI=10.1101/gr.147942.112; PMCID=PMC3589544

Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.

Dynamic DNA methylation across diverse human cell lines and tissues.

Genome Res. 23:555-567(2013)

PubMed=23404217; DOI=10.1007/s11626-013-9581-9

Chang D., Xu H.-W., Guo Y.-H., Jiang X., Liu Y., Li K.-L., Pan C.-X., Yuan M., Wang J.-F., Li T.-Z., Liu C.-T.

Simulated microgravity alters the metastatic potential of a human lung adenocarcinoma cell line.

In Vitro Cell. Dev. Biol. Anim. 49:170-177(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24135919; DOI=10.1038/ncomms3617; PMCID=PMC4107456

Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Nat. Commun. 4:2617.1-2617.13(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25120651; DOI=10.3892/ol.2014.2234; PMCID=PMC4114630

Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K., Shibata H., Ito T., Baba Y., Baba H.

Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.

Oncol. Lett. 8:1025-1030(2014)

PubMed=25475639; DOI=10.5731/pdajpst.2014.01027

Shabram P., Kolman J.L.

Evaluation of A549 as a new vaccine cell substrate: digging deeper with massively parallel sequencing.

PDA J. Pharm. Sci. Technol. 68:639-650(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477; PMCID=PMC4761227

Kitata R.B., Dimayacyac-Esleta B.R.T., Choong W.-K., Tsai C.-F., Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D., Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.

Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.

J. Proteome Res. 14:3658-3669(2015)

PubMed=26554430; DOI=10.1021/acs.analchem.5b03639

Dimayacyac-Esleta B.R.T., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.

Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.

Anal. Chem. 87:12016-12023(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28114404; DOI=10.1371/journal.pone.0170609; PMCID=PMC5256872

Fang Y.-N., Zhang C., Wu T., Wang Q., Liu J.-H., Dai P.-G.

Transcriptome sequencing reveals key pathways and genes associated with cisplatin resistance in lung adenocarcinoma A549 cells.

PLoS ONE 12:E0170609-E0170609(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28408844; DOI=10.2147/OTT.S128416; PMCID=PMC5384690

Townsend M.H., Anderson M.D., Weagel E.G., Velazquez E.J., Weber K.S., Robison R.A., O'Neill K.L.

Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane.

Onco Targets Ther. 10:1921-1932(2017)

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009; PMCID=PMC5493283

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Lindbjerg Andersen C., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

PubMed=28746345; DOI=10.1371/journal.pone.0181081; PMCID=PMC5528889

Sarin N., Engel F., Kalayda G.V., Mannewitz M., Cinatl J. Jr., Rothweiler F., Michaelis M., Saafan H., Ritter C.A., Jaehde U., Frotschl R.

Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.

PLoS ONE 12:E0181081-E0181081(2017)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

PubMed=29457907; DOI=10.1021/acs.jproteome.7b00782

Tomin T., Fritz K., Gindlhuber J., Waldherr L., Pucher B., Thallinger G.G., Nomura D.K., Schittmayer M., Birner-Gruenberger R.

Deletion of adipose triglyceride lipase links triacylglycerol accumulation to a more-aggressive phenotype in A549 lung carcinoma cells.

J. Proteome Res. 17:1415-1425(2018)

PubMed=29468137; DOI=10.5501/wjv.v7.i1.10; PMCID=PMC5807893

Himmelsbach K., Hildt E.

Identification of various cell culture models for the study of Zika virus.

World J. Virol. 7:10-20(2018)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028; PMCID=PMC5935540

McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti"